BACKGROUND: It has been reported that the c-erbB-2 protooncogene is frequently amplified and overexpressed in many types of cancers, except sarcomas and hematological malignancies. METHODS: Expression of ErbB-2 in the tumors of 26 patients with conventional osteosarcoma was evaluated by immunoblotting. DNA from osteosarcoma tissues that expressed ErbB-2 were analyzed by Southern blot hybridization to examine gross rearrangement of the gene. The DNA was also surveyed for the presence of genetic mutation in the transmembrane domain of ErbB-2 by polymerase chain reaction-single-stranded DNA conformation polymorphism analysis. In addition, possible correlation of ErbB-2 expression with gender, age, histopathologic subtype, and response to chemotherapy was analyzed. Survival analysis was performed by the Kaplan-Meier test using the approximate chi-square statistic for the log-rank test. RESULTS: The ErbB-2 protein was detected in 11 of 26 osteosarcoma tissues (42%) by immunoblot analysis. Expression of ErbB-2 was confirmed by immunohistochemical studies using specific anti-ErbB-2 monoclonal antibody. However, neither amplification of the c-erbB-2 gene nor evidence of significant genetic mutation was found in these osteosarcomas. Expression of ErbB-2 examined by immunoblotting was most strongly correlated with early pulmonary metastases (P < 0.05). Among the entire group of 26 patients in this study, Kaplan-Meier life table survival of the patients with apparent ErbB-2 expression was significantly worse than that of the patients with little ErbB-2 expression (P < 0.01). CONCLUSIONS: In 42% of the osteosarcomas, the tumor cells expressed ErbB-2. Expression of ErbB-2 was strongly correlated with early pulmonary metastasis and poor survival rate for the patient. These data suggest that ErbB-2 plays a significant role in aggressive tumor growth and in the promotion of metastatic potential in osteosarcomas. ErbB-2 in the osteosarcoma tissues would be a useful prognostic marker for patients.
BACKGROUND: It has been reported that the c-erbB-2 protooncogene is frequently amplified and overexpressed in many types of cancers, except sarcomas and hematological malignancies. METHODS: Expression of ErbB-2 in the tumors of 26 patients with conventional osteosarcoma was evaluated by immunoblotting. DNA from osteosarcoma tissues that expressed ErbB-2 were analyzed by Southern blot hybridization to examine gross rearrangement of the gene. The DNA was also surveyed for the presence of genetic mutation in the transmembrane domain of ErbB-2 by polymerase chain reaction-single-stranded DNA conformation polymorphism analysis. In addition, possible correlation of ErbB-2 expression with gender, age, histopathologic subtype, and response to chemotherapy was analyzed. Survival analysis was performed by the Kaplan-Meier test using the approximate chi-square statistic for the log-rank test. RESULTS: The ErbB-2 protein was detected in 11 of 26 osteosarcoma tissues (42%) by immunoblot analysis. Expression of ErbB-2 was confirmed by immunohistochemical studies using specific anti-ErbB-2 monoclonal antibody. However, neither amplification of the c-erbB-2 gene nor evidence of significant genetic mutation was found in these osteosarcomas. Expression of ErbB-2 examined by immunoblotting was most strongly correlated with early pulmonary metastases (P < 0.05). Among the entire group of 26 patients in this study, Kaplan-Meier life table survival of the patients with apparent ErbB-2 expression was significantly worse than that of the patients with little ErbB-2 expression (P < 0.01). CONCLUSIONS: In 42% of the osteosarcomas, the tumor cells expressed ErbB-2. Expression of ErbB-2 was strongly correlated with early pulmonary metastasis and poor survival rate for the patient. These data suggest that ErbB-2 plays a significant role in aggressive tumor growth and in the promotion of metastatic potential in osteosarcomas. ErbB-2 in the osteosarcoma tissues would be a useful prognostic marker for patients.
Authors: David Ebb; Paul Meyers; Holcombe Grier; Mark Bernstein; Richard Gorlick; Steven E Lipshultz; Mark Krailo; Meenakshi Devidas; Donald A Barkauskas; Gene P Siegal; William Shay Ferguson; George Douglas Letson; Karen Marcus; Allen Goorin; Peter Beardsley; Neyssa Marina Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Patrick J Messerschmitt; Ashley N Rettew; Robert E Brookover; Ryan M Garcia; Patrick J Getty; Edward M Greenfield Journal: Clin Orthop Relat Res Date: 2008-07-08 Impact factor: 4.176
Authors: Sarah Gorlick; Donald A Barkauskas; Mark Krailo; Sajida Piperdi; Rebecca Sowers; Jonathan Gill; David Geller; R Lor Randall; Katherine Janeway; Cindy Schwartz; Holcombe Grier; Paul A Meyers; Richard Gorlick; Mark Bernstein; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2014-04-22 Impact factor: 3.167
Authors: M Salem; Y Kinoshita; T Tajiri; R Souzaki; K Tatsuta; M Higashi; T Izaki; K Kohashi; M Tsuneyoshi; T Taguchi Journal: Pediatr Surg Int Date: 2006-11 Impact factor: 1.827
Authors: Arturo Muñoz; José Alfaro; Nuria Pardo; Purificación García-Miguel; Víctor Quintero; Luis Gros; Carmen Melero; María Jesús Antuña; Guillermo Ocete; Jorge de Las Heras; Manuel Ruiz del Portal; Ramón Huguet; María Soledad Maldonado Journal: Clin Transl Oncol Date: 2009-06 Impact factor: 3.405
Authors: G Valabrega; F Fagioli; S Corso; E Madon; A Brach del Prever; E Biasin; A Linari; M Aglietta; S Giordano Journal: Br J Cancer Date: 2003-02-10 Impact factor: 7.640